Cancer name Skin Cutaneous Melanoma
Cancer Type SKCM
Immunotherapy type Cancer Vaccine
Treatment M/CpG-ODN-TRP2-Lipo.
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Cell
Signature IFN-γ-producing cells
Official Symbol CD8+ cytotoxic T cell
Mode of action CE_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental Mouse model
Description In contrast, the number of activated T cells (CD3+CD25+ T cells; Figure 7C), TRP2-specific CD8+ CTLs (as detected by TRP2 tetramer; Figure 7D), and IFN-γ-producing cells (Figure 8E) in spleen significantly increased
PMID 29556352
Title The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP14 peptide